Thymosin Alpha-1

Not FDA approvedImmune Signaling ResearchRecovery & tissue repairImmune & gut
7.4

Strong recommend, BioHarmony verdict

BioHarmony score 7.4 out of 10

Thymosin Alpha-1 is a 28-amino-acid thymic peptide with strongest evidence in immune-compromised and hospital-adjacent settings: Cao 2024 pooled 39 acute COPD exacerbation RCTs, while TESTS 2025 found no clear 28-day sepsis mortality benefit.

Read full report

What is Thymosin Alpha-1?

Thymosin Alpha-1, also called thymalfasin or TA-1, is a 28-amino-acid thymic peptide used internationally as Zadaxin and in the United States through non-FDA-approved peptide channels. Its core role is immune modulation: TA-1 helps dendritic cells bridge innate and adaptive immunity, nudges T-helper signaling toward antiviral Th1 activity, supports CD4/CD8 recovery in lymphopenic states, and may improve monocyte HLA-DR expression in sepsis-induced immune suppression.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

TLR9 and TLR2 signaling on dendritic cells, NF-kB activation, Th1 polarization, CD4/CD8 normalization, NK-cell support, and IDO-mediated immune tolerance.

Safety watch-outs

  • Injection-site infection
  • Autoimmune flare symptoms

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Thymosin Alpha-1 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (4)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established

FDA identifies immunogenicity and peptide-impurity concerns for compounded thymosin alpha-1 and says available safety information is inadequate.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.